DE602004008291T2 - Substituierte piperidine als histamin-h3-rezeptorliganden - Google Patents

Substituierte piperidine als histamin-h3-rezeptorliganden Download PDF

Info

Publication number
DE602004008291T2
DE602004008291T2 DE602004008291T DE602004008291T DE602004008291T2 DE 602004008291 T2 DE602004008291 T2 DE 602004008291T2 DE 602004008291 T DE602004008291 T DE 602004008291T DE 602004008291 T DE602004008291 T DE 602004008291T DE 602004008291 T2 DE602004008291 T2 DE 602004008291T2
Authority
DE
Germany
Prior art keywords
piperidinyl
oxy
cyclobutyl
methylethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004008291T
Other languages
German (de)
English (en)
Other versions
DE602004008291D1 (de
Inventor
J. M. Bailey
Gordon Bruton
Anthony Huxley
Peter Henry Milner
B. S. Orlek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0316893A external-priority patent/GB0316893D0/en
Priority claimed from GB0411167A external-priority patent/GB0411167D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602004008291D1 publication Critical patent/DE602004008291D1/de
Application granted granted Critical
Publication of DE602004008291T2 publication Critical patent/DE602004008291T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE602004008291T 2003-07-18 2004-07-16 Substituierte piperidine als histamin-h3-rezeptorliganden Expired - Fee Related DE602004008291T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0316893A GB0316893D0 (en) 2003-07-18 2003-07-18 Novel compounds
GB0316893 2003-07-18
GB0411167 2004-05-19
GB0411167A GB0411167D0 (en) 2004-05-19 2004-05-19 Novel compounds
PCT/EP2004/008061 WO2005014571A1 (en) 2003-07-18 2004-07-16 Substituted piperidines as histamine h3 receptor ligands

Publications (2)

Publication Number Publication Date
DE602004008291D1 DE602004008291D1 (de) 2007-09-27
DE602004008291T2 true DE602004008291T2 (de) 2008-05-08

Family

ID=34137741

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004008291T Expired - Fee Related DE602004008291T2 (de) 2003-07-18 2004-07-16 Substituierte piperidine als histamin-h3-rezeptorliganden

Country Status (9)

Country Link
US (1) US20060247227A1 (enExample)
EP (1) EP1646620B1 (enExample)
JP (1) JP2006528147A (enExample)
AR (1) AR045999A1 (enExample)
AT (1) ATE370135T1 (enExample)
DE (1) DE602004008291T2 (enExample)
ES (1) ES2291913T3 (enExample)
TW (1) TW200514781A (enExample)
WO (1) WO2005014571A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010350A1 (en) * 2005-07-19 2007-01-25 Pfizer Products Inc. Synthesis of therapeutic diphenyl ethers
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
MX2010003398A (es) * 2007-09-28 2010-04-09 Schering Corp Derivados de oxipiperidina como antagonistas del receptor de histamina.
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5647339B2 (ja) 2010-05-17 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２アンタゴニスト及びこれらの使用
CN102260277B (zh) 2010-05-24 2013-07-24 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
KR101764952B1 (ko) * 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
CN104114538B (zh) * 2012-01-16 2016-04-13 葛兰素史克知识产权发展有限公司 治疗用途
JP2015503598A (ja) * 2012-01-16 2015-02-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 治療的使用
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
EP3317270B1 (en) 2015-07-02 2020-05-13 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
US10752587B2 (en) 2015-12-01 2020-08-25 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use
AU2023247609A1 (en) * 2022-03-31 2024-10-17 Bebetter Med Inc. 1,4-diheterocyclic substituted aromatic ring or aromatic heterocyclic compound and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US6906081B2 (en) * 2001-02-08 2005-06-14 Schering Corporation Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
EP2243776A1 (en) * 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
US7524852B2 (en) * 2002-06-07 2009-04-28 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives

Also Published As

Publication number Publication date
TW200514781A (en) 2005-05-01
US20060247227A1 (en) 2006-11-02
EP1646620A1 (en) 2006-04-19
ES2291913T3 (es) 2008-03-01
WO2005014571A1 (en) 2005-02-17
JP2006528147A (ja) 2006-12-14
EP1646620B1 (en) 2007-08-15
DE602004008291D1 (de) 2007-09-27
ATE370135T1 (de) 2007-09-15
AR045999A1 (es) 2005-11-23

Similar Documents

Publication Publication Date Title
DE602004008291T2 (de) Substituierte piperidine als histamin-h3-rezeptorliganden
DE60005560T2 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
DE60218511T2 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
DE602004007119T2 (de) 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's
DE60315062T2 (de) Triazolverbindungen zur behandlung von dysmenorrhoe
DE602005005080T2 (de) Pyrrolidinderivate als histaminrezeptor-liganden
DE69410784T2 (de) Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste
DE69723104T2 (de) Piridin-2-yl-methylamin-derivate, verfahren zu deren herstellung und ihre verwendung als arzneimittel
DE69516853T2 (de) Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten
EP1912939A1 (en) Metabotropic glutamate-receptor-potentiating isoindolones
KR20070106690A (ko) 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도
EP2114940A1 (en) Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
WO2008130853A1 (en) Hydrazides and their use as metabotropic glutamate receptor potentiators - 681
EP2061775A2 (en) Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
KR20180073685A (ko) 신경계 질환을 치료하기 위한, 무스카린성 수용체 4 (m4) 길항제로서의 n-[2-(1-벤질피페리딘-4-일)에틸]-4-(피라진-2-일)-피페라진-1-카르복스아미드 유도체 및 관련된 화합물
US7638631B2 (en) Methylene dipiperidine derivatives
EP3634955B1 (en) Piperidinone formyl peptide 2 receptor agonists
DE69123315T2 (de) 6,7-Dihydro-3-Phenyl-1,2-benzisoxazol-4(5H)-one und -ole, ein Verfahren für ihre Herstellung und ihre Verwendung als Arzneimittel
CA3179059A1 (en) Collagen 1 translation inhibitors and methods of use thereof
JP2006527267A (ja) 新規なアゼチジン化合物
KR20140014163A (ko) 알파 7 nAChR의 알로스테릭 조절자로서의 (피리딘-4-일)벤질아미드
EP2411363B1 (de) Substituierte piperidine als par-1 antagonisten
KR20070113225A (ko) 히스타민 ｈ３ 수용체에 대해 친화성을 갖는 융합된 티아졸유도체
CA3260221A1 (en) Substituted Fused Bicyclic Compounds and Associated Treatment Processes
KR20080050392A (ko) 대사성 글루타메이트 수용체 길항제로서 바이시클릭피페라진

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: HUXLEY, ANTHONY, HARLOW ESSEX CM19 5AW, GB

Inventor name: BRUTON, GORDON, HARLOW ESSEX CM19 5AW, GB

Inventor name: ORLEK, B. S., HARLOW ESSEX CM19 5AW, GB

Inventor name: MILNER, PETER HENRY, HARLOW ESSEX CM19 5AW, GB

Inventor name: BAILEY, J. M., HARLOW ESSEX CM19 5AW, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee